What Could Go Wrong At UnitedHealth From Here?
For questions about this article or underlying research, email help@trefis.com.
UnitedHealth Group (UNH) stock returned 27.0% over the past twelve months, against 12.2% for the S&P 500. On its October 13, 2026 call, management said it is confident it can grow in 2027 and beyond. Yet during that same call, management called one cost a particular concern within the company’s largest business. So what is the cost that management singled out?
UnitedHealth’s Commercial Care Costs Are Higher Than Planned
The cost is medical care in UnitedHealth’s commercial business, and the part management singled out is abuse of the No Surprises Act dispute process. On the October 13 call, management said cost trends for commercial benefits are exceeding the 11% it first expected, driven by costs tied to the No Surprises Act, more costly care from clinicians and high-cost specialty drugs. Management added that the commercial trend has stabilized somewhat in recent months, but is still running above 11%.
The No Surprises Act is the sharpest part of the complaint. Management said a relatively small number of clinician groups and third-party organizations are abusing its dispute process, and that arbitration awards can approach nearly 6% of total medical spend in some regions.
Management also said these costs will delay when it reaches its long-term margin goals for the commercial business, and it promised more detail in a couple of months.
Where Do These Costs Sit In UnitedHealth’s Business?
The commercial business sits inside UnitedHealthcare, the company’s largest segment. This segment had revenue of $345 billion in fiscal 2025, up 15.7% from fiscal 2024, and it also runs the company’s Medicare and Medicaid plans.
Profit across the whole company is thin. UnitedHealth’s operating margin was 5.3% over the twelve months to September 2026, down from 6.1% a year earlier. The September quarter alone improved, to 5.8% from 3.8% in the same quarter of 2025, so UnitedHealth is in the middle of a margin recovery. Its twelve-month margin has also climbed back from a low of 4.2% in the twelve months to March 2026.
UnitedHealth stock closed at $405.13 on November 12, 2026, only 6.6% below its highest close of the past year. At that price UnitedHealth trades at 22.9 times its trailing earnings, a small premium to the 21.9 for the S&P 500, even though its twelve-month margin is still below where it was a year earlier. That multiple uses reported profit, and UnitedHealth earned just $0.01 billion in the fourth quarter of 2025. On management’s 2026 adjusted EPS guide of at least $20.50, the stock trades near 19.8 times.
How Worried Should UnitedHealth Holders Be?
The commercial cost pressure looks like a real but slow risk to UnitedHealth’s margin recovery. Management has already set its 2027 prices on the view that these costs persist, so the pressure looks more likely to show up as a slower climb in commercial margins than as a sudden hit.
Management’s commercial cost trend, last put above 11%, is the figure to watch when UnitedHealth gives its 2027 outlook before the end of 2026. It will also be the metric to watch when the company reports fourth-quarter results, expected in January 2027.
Does This Mean You Should Act On UNH?
Betting on a single stock is always risky, whichever way you lean. The Trefis High Quality (HQ) Portfolio holds 30 quality companies in equal weight and has returned 105% since its September 2020 launch.
Spot an error or want more like this? Tell us in 10 seconds.